TY - JOUR PY - 2018 DA - 2018// TI - GLOBOCAN 2018: counting the toll of cancer JO - Lancet VL - 392 UR - https://doi.org/10.1016/S0140-6736(18)32252-9 DO - 10.1016/S0140-6736(18)32252-9 ID - ref1 ER - TY - JOUR AU - Matulonis, U. A. AU - Sood, A. K. AU - Fallowfield, L. AU - Howitt, B. E. AU - Sehouli, J. AU - Karlan, B. Y. PY - 2016 DA - 2016// TI - Ovarian cancer JO - Nat Rev Dis Primers VL - 2 UR - https://doi.org/10.1038/nrdp.2016.61 DO - 10.1038/nrdp.2016.61 ID - Matulonis2016 ER - TY - JOUR AU - Karam, A. AU - Ledermann, J. A. AU - Kim, J. W. AU - Sehouli, J. AU - Lu, K. AU - Gourley, C. PY - 2017 DA - 2017// TI - Fifth ovarian Cancer consensus conference of the gynecologic Cancer InterGroup: first-line interventions JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx011 DO - 10.1093/annonc/mdx011 ID - Karam2017 ER - TY - JOUR AU - Pignata, S. AU - Scambia, G. AU - Ferrandina, G. AU - Savarese, A. AU - Sorio, R. AU - Breda, E. PY - 2011 DA - 2011// TI - Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.8566 DO - 10.1200/JCO.2010.33.8566 ID - Pignata2011 ER - TY - JOUR AU - Pignata, S. AU - Cannella, L. AU - Leopardo, D. AU - Pisano, C. AU - Bruni, G. S. AU - Facchini, G. PY - 2011 DA - 2011// TI - Chemotherapy in epithelial ovarian cancer JO - Cancer Lett VL - 303 UR - https://doi.org/10.1016/j.canlet.2011.01.026 DO - 10.1016/j.canlet.2011.01.026 ID - Pignata2011 ER - TY - JOUR AU - Vasey, P. A. AU - Jayson, G. C. AU - Gordon, A. AU - Gabra, H. AU - Coleman, R. AU - Atkinson, R. PY - 2004 DA - 2004// TI - Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma JO - J Natl Cancer Inst VL - 96 UR - https://doi.org/10.1093/jnci/djh323 DO - 10.1093/jnci/djh323 ID - Vasey2004 ER - TY - JOUR AU - Kim, S. AU - Han, Y. AU - Kim, S. I. AU - Kim, H. S. AU - Kim, S. J. AU - Song, Y. S. PY - 2018 DA - 2018// TI - Tumor evolution and chemoresistance in ovarian cancer JO - NPJ Precis Oncol VL - 2 UR - https://doi.org/10.1038/s41698-018-0063-0 DO - 10.1038/s41698-018-0063-0 ID - Kim2018 ER - TY - JOUR AU - Janda, M. AU - McGrath, S. AU - Obermair, A. PY - 2019 DA - 2019// TI - Challenges and controversies in the conservative management of uterine and ovarian cancer JO - Best Practice & Research Clinical Obstetrics & Gynaecology VL - 55 UR - https://doi.org/10.1016/j.bpobgyn.2018.08.004 DO - 10.1016/j.bpobgyn.2018.08.004 ID - Janda2019 ER - TY - JOUR AU - Mallen, A. AU - Soong, T. R. AU - Townsend, M. K. AU - Wenham, R. M. AU - Crum, C. P. AU - Tworoger, S. S. PY - 2018 DA - 2018// TI - Surgical prevention strategies in ovarian cancer JO - Gynecol Oncol VL - 151 UR - https://doi.org/10.1016/j.ygyno.2018.08.005 DO - 10.1016/j.ygyno.2018.08.005 ID - Mallen2018 ER - TY - JOUR AU - Siddik, Z. H. PY - 2003 DA - 2003// TI - Cisplatin: mode of cytotoxic action and molecular basis of resistance JO - Oncogene VL - 22 UR - https://doi.org/10.1038/sj.onc.1206933 DO - 10.1038/sj.onc.1206933 ID - Siddik2003 ER - TY - JOUR AU - Galluzzi, L. AU - Senovilla, L. AU - Vitale, I. AU - Michels, J. AU - Martins, I. AU - Kepp, O. PY - 2012 DA - 2012// TI - Molecular mechanisms of cisplatin resistance JO - Oncogene VL - 31 UR - https://doi.org/10.1038/onc.2011.384 DO - 10.1038/onc.2011.384 ID - Galluzzi2012 ER - TY - JOUR AU - Stewart, D. J. PY - 2007 DA - 2007// TI - Mechanisms of resistance to cisplatin and carboplatin JO - Crit Rev Oncol Hematol VL - 63 UR - https://doi.org/10.1016/j.critrevonc.2007.02.001 DO - 10.1016/j.critrevonc.2007.02.001 ID - Stewart2007 ER - TY - JOUR AU - Shen, D. W. AU - Pouliot, L. M. AU - Hall, M. D. AU - Gottesman, M. M. PY - 2012 DA - 2012// TI - Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes JO - Pharmacol Rev VL - 64 UR - https://doi.org/10.1124/pr.111.005637 DO - 10.1124/pr.111.005637 ID - Shen2012 ER - TY - JOUR AU - Gee, M. E. AU - Faraahi, Z. AU - McCormick, A. AU - Edmondson, R. J. PY - 2018 DA - 2018// TI - DNA damage repair in ovarian cancer: unlocking the heterogeneity JO - J Ovarian Res VL - 11 UR - https://doi.org/10.1186/s13048-018-0424-x DO - 10.1186/s13048-018-0424-x ID - Gee2018 ER - TY - JOUR AU - Roy, L. y. n. n. AU - Cowden Dahl, K. a. r. e. n. PY - 2018 DA - 2018// TI - Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer? JO - Cancers VL - 10 UR - https://doi.org/10.3390/cancers10080241 DO - 10.3390/cancers10080241 ID - Roy2018 ER - TY - JOUR AU - Muinao, T. AU - Deka Boruah, H. P. AU - Pal, M. PY - 2018 DA - 2018// TI - Diagnostic and prognostic biomarkers in ovarian cancer and the potential roles of cancer stem cells - an updated review JO - Exp Cell Res VL - 362 UR - https://doi.org/10.1016/j.yexcr.2017.10.018 DO - 10.1016/j.yexcr.2017.10.018 ID - Muinao2018 ER - TY - JOUR AU - Pylvas-Eerola, M. AU - Liakka, A. AU - Puistola, U. AU - Koivunen, J. AU - Karihtala, P. PY - 2016 DA - 2016// TI - Cancer stem cell properties as factors predictive of chemoresistance in neoadjuvantly-treated patients with ovarian Cancer JO - Anticancer Res VL - 36 ID - Pylvas-Eerola2016 ER - TY - JOUR AU - Farnie, G. AU - Clarke, R. B. PY - 2007 DA - 2007// TI - Mammary stem cells and breast cancer--role of Notch signalling JO - Stem Cell Rev VL - 3 UR - https://doi.org/10.1007/s12015-007-0023-5 DO - 10.1007/s12015-007-0023-5 ID - Farnie2007 ER - TY - JOUR AU - Klemba, A. AU - Purzycka-Olewiecka, J. K. AU - Wcislo, G. AU - Czarnecka, A. M. AU - Lewicki, S. AU - Lesyng, B. PY - 2018 DA - 2018// TI - Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance JO - Contemp Oncol VL - 22 ID - Klemba2018 ER - TY - JOUR AU - Steg, A. D. AU - Bevis, K. S. AU - Katre, A. A. AU - Ziebarth, A. AU - Dobbin, Z. C. AU - Alvarez, R. D. PY - 2012 DA - 2012// TI - Stem cell pathways contribute to clinical chemoresistance in ovarian cancer JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-2188 DO - 10.1158/1078-0432.CCR-11-2188 ID - Steg2012 ER - TY - JOUR AU - Kryczek, I. AU - Liu, S. AU - Roh, M. AU - Vatan, L. AU - Szeliga, W. AU - Wei, S. PY - 2012 DA - 2012// TI - Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells JO - Int J Cancer VL - 130 UR - https://doi.org/10.1002/ijc.25967 DO - 10.1002/ijc.25967 ID - Kryczek2012 ER - TY - JOUR AU - Lee, C. H. AU - Yu, C. C. AU - Wang, B. Y. AU - Chang, W. W. PY - 2016 DA - 2016// TI - Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.6261 DO - 10.18632/oncotarget.6261 ID - Lee2016 ER - TY - JOUR AU - Wang, L. AU - Xu, T. AU - Cui, M. PY - 2018 DA - 2018// TI - Are ovarian cancer stem cells the target for innovative immunotherapy? JO - Onco Targets Ther VL - 11 UR - https://doi.org/10.2147/OTT.S155458 DO - 10.2147/OTT.S155458 ID - Wang2018 ER - TY - JOUR AU - Markowska, A. AU - Sajdak, S. AU - Huczynski, A. AU - Rehlis, S. AU - Markowska, J. PY - 2018 DA - 2018// TI - Ovarian cancer stem cells: a target for oncological therapy JO - Adv Clin Exp Med VL - 27 UR - https://doi.org/10.17219/acem/73999 DO - 10.17219/acem/73999 ID - Markowska2018 ER - TY - JOUR AU - Ottevanger, P. B. PY - 2017 DA - 2017// TI - Ovarian cancer stem cells more questions than answers JO - Semin Cancer Biol VL - 44 UR - https://doi.org/10.1016/j.semcancer.2017.04.009 DO - 10.1016/j.semcancer.2017.04.009 ID - Ottevanger2017 ER - TY - JOUR AU - Burgos-Ojeda, D. AU - Rueda, B. R. AU - Buckanovich, R. J. PY - 2012 DA - 2012// TI - Ovarian cancer stem cell markers: prognostic and therapeutic implications JO - Cancer Lett VL - 322 UR - https://doi.org/10.1016/j.canlet.2012.02.002 DO - 10.1016/j.canlet.2012.02.002 ID - Burgos-Ojeda2012 ER - TY - JOUR AU - Zhang, X. L. AU - Jia, Q. AU - Lv, L. AU - Deng, T. AU - Gao, J. PY - 2015 DA - 2015// TI - Tumorspheres derived from HCC cells are enriched with Cancer stem cell-like cells and present high Chemoresistance dependent on the Akt pathway JO - Anti Cancer Agents Med Chem VL - 15 UR - https://doi.org/10.2174/1871520615666150202111721 DO - 10.2174/1871520615666150202111721 ID - Zhang2015 ER - TY - JOUR AU - Zhang, L. AU - Jiao, M. AU - Li, L. AU - Wu, D. AU - Wu, K. AU - Li, X. PY - 2012 DA - 2012// TI - Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties JO - J Cancer Res Clin Oncol VL - 138 UR - https://doi.org/10.1007/s00432-011-1146-2 DO - 10.1007/s00432-011-1146-2 ID - Zhang2012 ER - TY - JOUR AU - Carnero, A. AU - Garcia-Mayea, Y. AU - Mir, C. AU - Lorente, J. AU - Rubio, I. T. AU - ME, L. L. PY - 2016 DA - 2016// TI - The cancer stem-cell signaling network and resistance to therapy JO - Cancer Treat Rev VL - 49 UR - https://doi.org/10.1016/j.ctrv.2016.07.001 DO - 10.1016/j.ctrv.2016.07.001 ID - Carnero2016 ER - TY - JOUR AU - Morrison, S. J. AU - Kimble, J. PY - 2006 DA - 2006// TI - Asymmetric and symmetric stem-cell divisions in development and cancer JO - Nature VL - 441 UR - https://doi.org/10.1038/nature04956 DO - 10.1038/nature04956 ID - Morrison2006 ER - TY - JOUR AU - Cao, D. AU - Kishida, S. AU - Huang, P. AU - Mu, P. AU - Tsubota, S. AU - Mizuno, M. PY - 2014 DA - 2014// TI - A new tumorsphere culture condition restores potentials of self-renewal and metastasis of primary neuroblastoma in a mouse neuroblastoma model JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0086813 DO - 10.1371/journal.pone.0086813 ID - Cao2014 ER - TY - JOUR AU - Amable, L. PY - 2016 DA - 2016// TI - Cisplatin resistance and opportunities for precision medicine JO - Pharmacol Res VL - 106 UR - https://doi.org/10.1016/j.phrs.2016.01.001 DO - 10.1016/j.phrs.2016.01.001 ID - Amable2016 ER - TY - JOUR AU - Alkema, N. G. AU - Wisman, G. B. AU - Zee, A. G. AU - Vugt, M. A. AU - Jong, S. PY - 2016 DA - 2016// TI - Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions JO - Drug Resist Updat VL - 24 UR - https://doi.org/10.1016/j.drup.2015.11.005 DO - 10.1016/j.drup.2015.11.005 ID - Alkema2016 ER - TY - JOUR AU - Liu, X. AU - Gao, Y. AU - Zhao, B. AU - Li, X. AU - Lu, Y. AU - Zhang, J. PY - 2015 DA - 2015// TI - Discovery of microarray-identified genes associated with ovarian cancer progression JO - Int J Oncol VL - 46 UR - https://doi.org/10.3892/ijo.2015.2971 DO - 10.3892/ijo.2015.2971 ID - Liu2015 ER - TY - JOUR AU - Liu, X. AU - Gao, Y. AU - Lu, Y. AU - Zhang, J. AU - Li, L. AU - Yin, F. PY - 2015 DA - 2015// TI - Oncogenes associated with drug resistance in ovarian cancer JO - J Cancer Res Clin Oncol VL - 141 UR - https://doi.org/10.1007/s00432-014-1765-5 DO - 10.1007/s00432-014-1765-5 ID - Liu2015 ER - TY - JOUR AU - Chudasama, D. AU - Bo, V. AU - Hall, M. AU - Anikin, V. AU - Jeyaneethi, J. AU - Gregory, J. PY - 2018 DA - 2018// TI - Identification of cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers JO - Carcinogenesis VL - 39 UR - https://doi.org/10.1093/carcin/bgx122 DO - 10.1093/carcin/bgx122 ID - Chudasama2018 ER - TY - JOUR AU - Elsnerova, K. AU - Bartakova, A. AU - Tihlarik, J. AU - Bouda, J. AU - Rob, L. AU - Skapa, P. PY - 2017 DA - 2017// TI - Gene expression profiling reveals novel candidate markers of ovarian carcinoma intraperitoneal metastasis JO - J Cancer VL - 8 UR - https://doi.org/10.7150/jca.20766 DO - 10.7150/jca.20766 ID - Elsnerova2017 ER - TY - STD TI - Tarhriz V, Bandehpour M, Dastmalchi S, Ouladsahebmadarek E, Zarredar H, Eyvazi S. Overview of CD24 as a new molecular marker in ovarian cancer. J Cell Physiol. 2018. ID - ref38 ER - TY - JOUR AU - Shen, J. AU - Zhu, X. AU - Fei, J. AU - Shi, P. AU - Yu, S. AU - Zhou, J. PY - 2018 DA - 2018// TI - Advances of exosome in the development of ovarian cancer and its diagnostic and therapeutic prospect JO - OncoTargets Ther VL - 11 UR - https://doi.org/10.2147/OTT.S159829 DO - 10.2147/OTT.S159829 ID - Shen2018 ER - TY - JOUR AU - Li, S. S. AU - Ma, J. AU - Wong, A. S. T. PY - 2018 DA - 2018// TI - Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism JO - J Gynecol Oncol VL - 29 UR - https://doi.org/10.3802/jgo.2018.29.e32 DO - 10.3802/jgo.2018.29.e32 ID - Li2018 ER - TY - JOUR AU - Norouzi-Barough, L. AU - Sarookhani, M. R. AU - Sharifi, M. AU - Moghbelinejad, S. AU - Jangjoo, S. AU - Salehi, R. PY - 2018 DA - 2018// TI - Molecular mechanisms of drug resistance in ovarian cancer JO - J Cell Physiol VL - 233 UR - https://doi.org/10.1002/jcp.26289 DO - 10.1002/jcp.26289 ID - Norouzi-Barough2018 ER - TY - JOUR AU - Cioffi, M. AU - D’Alterio, C. AU - Camerlingo, R. AU - Tirino, V. AU - Consales, C. AU - Riccio, A. PY - 2015 DA - 2015// TI - Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer JO - Sci Rep VL - 5 UR - https://doi.org/10.1038/srep10357 DO - 10.1038/srep10357 ID - Cioffi2015 ER - TY - JOUR AU - Jimenez-Garcia, M. P. AU - Lucena-Cacace, A. AU - Robles-Frias, M. J. AU - Ferrer, I. AU - Narlik-Grassow, M. AU - Blanco-Aparicio, C. PY - 2017 DA - 2017// TI - Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.19438 DO - 10.18632/oncotarget.19438 ID - Jimenez-Garcia2017 ER - TY - JOUR AU - Pagotto, A. AU - Pilotto, G. AU - Mazzoldi, E. L. AU - Nicoletto, M. O. AU - Frezzini, S. AU - Pasto, A. PY - 2017 DA - 2017// TI - Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells JO - Cell Death Dis VL - 8 UR - https://doi.org/10.1038/cddis.2017.327 DO - 10.1038/cddis.2017.327 ID - Pagotto2017 ER - TY - JOUR AU - Nakamura, K. AU - Terai, Y. AU - Tanabe, A. AU - Ono, Y. J. AU - Hayashi, M. AU - Maeda, K. PY - 2017 DA - 2017// TI - CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways JO - Oncol Rep VL - 37 UR - https://doi.org/10.3892/or.2017.5583 DO - 10.3892/or.2017.5583 ID - Nakamura2017 ER - TY - JOUR AU - Saydaminova, K. AU - Strauss, R. AU - Xie, M. AU - Bartek, J. AU - Richter, M. AU - Rensburg, R. PY - 2016 DA - 2016// TI - Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells JO - Cancer Biol Ther VL - 17 UR - https://doi.org/10.1080/15384047.2016.1219819 DO - 10.1080/15384047.2016.1219819 ID - Saydaminova2016 ER - TY - JOUR AU - Wiechert, A. AU - Saygin, C. AU - Thiagarajan, P. S. AU - Rao, V. S. AU - Hale, J. S. AU - Gupta, N. PY - 2016 DA - 2016// TI - Cisplatin induces stemness in ovarian cancer JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.8852 DO - 10.18632/oncotarget.8852 ID - Wiechert2016 ER - TY - JOUR AU - Walters Haygood, C. L. AU - Arend, R. C. AU - Straughn, J. M. AU - Buchsbaum, D. J. PY - 2014 DA - 2014// TI - Ovarian cancer stem cells: can targeted therapy lead to improved progression-free survival? JO - World J Stem Cells VL - 6 UR - https://doi.org/10.4252/wjsc.v6.i4.441 DO - 10.4252/wjsc.v6.i4.441 ID - Walters Haygood2014 ER - TY - JOUR AU - Zhang, Q. H. AU - Dou, H. T. AU - Xu, P. AU - Zhuang, S. C. AU - Liu, P. S. PY - 2015 DA - 2015// TI - Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer JO - Drug Res VL - 65 ID - Zhang2015 ER -